These compounds showed a similarity score with the PPAR-γ receptor (Table 2), which is also the target receptor for the drug ORLISTAT® and acts either as an agonist, inhibiting the action of pancreatic lipases, or as a blocker of about 30% of the fats ingested by the patient (“[Pharmacological treatment of obesity]—PubMed,” n.d.). Here, PNLIP is linked to obesity disorder.